Today, at the premises of the Single Distributor, a meeting was held with the leaders of the PQM+ program “Promoting the Quality of Medicines” of the United States Agency for International Development (USAID).
The meeting was attended by MD, MPH Senior Advisor for Health Management, USAID Asia Bureau - Jean-Jacques Freret, Director of Core Technical Programs PQM+ - Archil Salakaya, Director of Pharmaceutical Strategy PQM+ - Ian K. Wartin, Director of CMC and Vaccines PQM+ – Zlatka Kostova Lenard, technical advisor, PQM+ – Didar Nurgozhina.
The parties discussed the current state of the pharmaceutical industry in Kazakhstan, as well as achievements, obstacles and development directions in the pharmaceutical industry. The discussion also gave the parties the opportunity to identify specific goals and objectives for enhanced cooperation between the Single Distributor and the PQM+ Program.
“PQM+” is a drug quality promotion program, which is carried out within the framework of the Cooperation Agreement between USAID and USP, in order to strengthen systems for ensuring the quality of pharmaceutical products. This program, also administered by USP, provides technical assistance to sustainably strengthen drug quality systems to achieve desired public health goals.
The goals of the PQM+ program in Kazakhstan are to improve the management of the quality assurance system for medical products, increase the supply of basic medical products of guaranteed quality that are important for public health, etc.
During the meeting, the head of the Unified Distributor, Erkhat Iskaliev, spoke in detail about the centralized procurement system operating in Kazakhstan and the role of the Unified Distributor in the drug supply system.
In addition, the participants were informed about the current situation, future plans and potential prospects for the development of the country's pharmaceutical industry. In particular, such domestic initiatives were presented as the formation of pharmaceutical clusters for the development of innovative medicines and medical devices in Kazakhstan, as well as cooperation initiatives with companies producing original drugs, raw materials for the production of medicines and medical devices.
At the end of the meeting, the parties expressed gratitude for the constructive dialogue that took place and voiced opportunities for increasing bilateral cooperation in the field of pharmaceutical production. It was noted that it is necessary to consolidate joint efforts in order to achieve more effective development indicators for the pharmaceutical industry and develop its competitiveness in the global market.
The single distributor, for its part, is ready to cooperate and assist in coordinating issues that arise in the process for the improvement and development of the country’s pharmaceutical sector and the healthcare sector as a whole.
For reference:
The Program for Promoting Quality in Medicines (PQM+) is a six-year cooperative agreement between the United States Agency for International Development (USAID) and the United States Pharmacopoeial Convention (USP) to sustainably strengthen health care product quality systems in low- and middle-income countries. PQM+ works to improve the quality of medical products through cross-industry and systems strengthening approaches, and the application of international quality assurance standards throughout the pharmaceutical system - in regulatory authorities, quality control laboratories, manufacturing plants and beyond.
The United States Agency for International Development (USAID) is the highest federal government agency of the United States of America in the field of providing foreign assistance. The Agency Administrator and his Deputy are appointed by the President with the consent of the Senate and act in coordination with the United States Secretary of State].
The United States Pharmacopoeial Convention (USP) is a nonprofit, non-governmental health care organization that develops documented standards and produces reference materials for prescription and over-the-counter drugs recognized by US law. USP's mission is to improve healthcare worldwide through government standards and related programs that help ensure the quality, safety and effectiveness of medicines and foods. Works closely with the US Food and Drug Administration (FDA), the government regulatory agency that oversees food products,
medicines and medical devices, and monitors the implementation of USP standards. Drug manufacturers planning to import or place their products on the US market must meet the standards defined by the USP.
Today, at the premises of the Single Distributor, a meeting was held with the leaders of the PQM+ program “Promoting the Quality of Medicines” of the United States Agency for International Development (USAID).
The meeting was attended by MD, MPH Senior Advisor for Health Management, USAID Asia Bureau - Jean-Jacques Freret, Director of Core Technical Programs PQM+ - Archil Salakaya, Director of Pharmaceutical Strategy PQM+ - Ian K. Wartin, Director of CMC and Vaccines PQM+ – Zlatka Kostova Lenard, technical advisor, PQM+ – Didar Nurgozhina.
The parties discussed the current state of the pharmaceutical industry in Kazakhstan, as well as achievements, obstacles and development directions in the pharmaceutical industry. The discussion also gave the parties the opportunity to identify specific goals and objectives for enhanced cooperation between the Single Distributor and the PQM+ Program.
“PQM+” is a drug quality promotion program, which is carried out within the framework of the Cooperation Agreement between USAID and USP, in order to strengthen systems for ensuring the quality of pharmaceutical products. This program, also administered by USP, provides technical assistance to sustainably strengthen drug quality systems to achieve desired public health goals.
The goals of the PQM+ program in Kazakhstan are to improve the management of the quality assurance system for medical products, increase the supply of basic medical products of guaranteed quality that are important for public health, etc.
During the meeting, the head of the Unified Distributor, Erkhat Iskaliev, spoke in detail about the centralized procurement system operating in Kazakhstan and the role of the Unified Distributor in the drug supply system.
In addition, the participants were informed about the current situation, future plans and potential prospects for the development of the country's pharmaceutical industry. In particular, such domestic initiatives were presented as the formation of pharmaceutical clusters for the development of innovative medicines and medical devices in Kazakhstan, as well as cooperation initiatives with companies producing original drugs, raw materials for the production of medicines and medical devices.
At the end of the meeting, the parties expressed gratitude for the constructive dialogue that took place and voiced opportunities for increasing bilateral cooperation in the field of pharmaceutical production. It was noted that it is necessary to consolidate joint efforts in order to achieve more effective development indicators for the pharmaceutical industry and develop its competitiveness in the global market.
The single distributor, for its part, is ready to cooperate and assist in coordinating issues that arise in the process for the improvement and development of the country’s pharmaceutical sector and the healthcare sector as a whole.
For reference:
The Program for Promoting Quality in Medicines (PQM+) is a six-year cooperative agreement between the United States Agency for International Development (USAID) and the United States Pharmacopoeial Convention (USP) to sustainably strengthen health care product quality systems in low- and middle-income countries. PQM+ works to improve the quality of medical products through cross-industry and systems strengthening approaches, and the application of international quality assurance standards throughout the pharmaceutical system - in regulatory authorities, quality control laboratories, manufacturing plants and beyond.
The United States Agency for International Development (USAID) is the highest federal government agency of the United States of America in the field of providing foreign assistance. The Agency Administrator and his Deputy are appointed by the President with the consent of the Senate and act in coordination with the United States Secretary of State].
The United States Pharmacopoeial Convention (USP) is a nonprofit, non-governmental health care organization that develops documented standards and produces reference materials for prescription and over-the-counter drugs recognized by US law. USP's mission is to improve healthcare worldwide through government standards and related programs that help ensure the quality, safety and effectiveness of medicines and foods. Works closely with the US Food and Drug Administration (FDA), the government regulatory agency that oversees food products,
medicines and medical devices, and monitors the implementation of USP standards. Drug manufacturers planning to import or place their products on the US market must meet the standards defined by the USP.
.jpeg)